New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
08:34 EDTVNDA, NVSVanda requests award of $539M in proceedings with Novartis
Vanda Pharmaceuticals (VNDA) announced that Novartis (NVS) had disclosed in its financial report for the quarter ended June 30 that Novartis is a respondent and counter-claimant in an arbitration proceeding commenced by Vanda Pharmaceuticals in May relating to the license of Fanapt. Vanda has requested an award of approximately $539M in such proceedings. Vanda said it is vigorously prosecuting its claims in the arbitration as well as defending counterclaims brought by Novartis. Vanda currently anticipates that the arbitration proceeding will be completed within 12 to 18 months.
News For VNDA;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
09:07 EDTVNDAVanda has new Hetlioz patent listed in FDA Orange Book
Vanda announced that a Hetlioz patent is now listed in the FDA publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The 'patent was issued by the USPTO on June 23rd and expires in January 2033.
07:27 EDTVNDAPublic Citizen calls on FDA to correct labeling of Vanda's Hetlioz drug
Subscribe for More Information
July 1, 2015
05:16 EDTNVSNovartis division Alcon receives CE Mark for AcryS of IQ Aspheric IOL
Subscribe for More Information
June 30, 2015
05:32 EDTNVSNovartis launches first Apple Watch app for visually impaired people
Novartis Pharmaceuticals (NVS) announced the release of new features for its ViaOpta applications, and the extension for use with smart watches. The discreet, hands-free nature of using ViaOpta app with wearable devices, such as Apple Watch (AAPL) and Android Wear (GOOG), provides users with an experience that seamlessly fits into their existing routines allowing those with visual impairments to navigate daily life with even greater ease.
June 29, 2015
08:35 EDTNVSAnacor announces amendment to KERYDIN commercialization agreement
Subscribe for More Information
05:15 EDTNVSNovartis acquires Spinifex Pharmaceuticals, terms not disclosed
Novartis announced that it has entered into an agreement to acquire Spinifex Pharmaceuticals. Spinifex Pharmaceuticals is a U.S. and Australian-based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain such as EMA401, a novel angiotensin II Type 2 receptor, or AT2R, antagonist. Financial terms were not disclosed.
June 26, 2015
07:44 EDTNVSNovartis drug Farydak recommended by CHMP for EU approval
Subscribe for More Information
June 25, 2015
14:02 EDTNVSNovartis initiated with a Buy at HSBC
Price target CHF 115.
June 24, 2015
10:03 EDTVNDAHigh option volume stocks: VNDA SN ADHD UNIS
June 23, 2015
19:03 EDTVNDAOn The Fly: After Hours Movers
UP AFTER PROVIDING GUIDANCE: MeetMe (MEET), up 18.8%. ALSO HIGHER: Nektar Therapeutics (NKTR), up 4.3% after being added to S&P 600... Quidel (QDEL), up 5% after receiving FDA clearance for new Solana molecular system and assay... Vanda Pharmaceuticals (VNDA), up 4.6% after announcing positive results from REPRIEVE study... Netflix (NFLX), up 3.4% after announcing seven-for-one stock split. LOWER: Alcobra (ADHD), down 2.5% after announcing that it will host a conference call and simultaneous webcast presentation to present results from the Phase II clinical trial of MDX... Sysco (SYY), down 2.6% after bid for U.S. foods blocked was blocked by a federal judge... Boeing (BA), down marginally after announcing CEO transition.
16:32 EDTVNDAVanda announces positive results from REPRIEVE study
Subscribe for More Information
07:36 EDTVNDAJMP Securities to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use